Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fougera, a division of Nycomed US, has received FDA approval to bring to market the first generic Calcipotriene Topical Solution 0.005%. The generic formulation compares to Dovonex by Warner-Chilcott.
Subscribe to our email newsletter
Fougera’s Calcipotriene Topical Solution (scalp solution) is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp. It is available in a 60ml bottle.
David Klaum, senior vice president, commercial business operations, Fougera, said: “Fougera has received more FDA approvals for topical products during the past seven years than any other generic company.”